- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | Erasca (ERAS) Adds 13%; Soars 310% YTD | 1 | Insider Monkey | ||
| ERASCA Aktie jetzt für 0€ handeln | |||||
| 12.03. | Erasca GAAP EPS of -$0.19 | 1 | Seeking Alpha | ||
| 12.03. | Erasca, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | 259 | GlobeNewswire (Europe) | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| 12.03. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | Stifel raises Erasca stock price target to $20 on China expansion | 1 | Investing.com | ||
| 10.03. | Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 | 1 | Investing.com | ||
| 06.03. | Clear Street raises Erasca stock price target on combination trial deal | 1 | Investing.com | ||
| 05.03. | Tango rises after Q4 results, clinical pact with Erasca | 1 | Seeking Alpha | ||
| 05.03. | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | 629 | GlobeNewswire (Europe) | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| 28.02. | Erasca, Inc. (ERAS): A Bull Case Theory | 2 | Insider Monkey | ||
| 24.02. | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | 475 | GlobeNewswire (Europe) | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| 09.02. | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | 3 | Investing.com Deutsch | ||
| 09.02. | Stifel reiterates Buy rating on Erasca stock, maintains $10 price target | 2 | Investing.com | ||
| 30.01. | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | 3 | Insider Monkey | ||
| 29.01. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.01. | Guggenheim raises Erasca stock price target to $12 on RAS inhibitor progress | 3 | Investing.com | ||
| 27.01. | Fortschritte bei RAS-Inhibitor: Guggenheim hebt Erasca-Kursziel auf 12 Dollar an | 1 | Investing.com Deutsch | ||
| 26.01. | Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? | 3 | Benzinga.com | ||
| 26.01. | Erasca stock price target raised to $15 from $11 at H.C. Wainwright | 2 | Investing.com |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,70 | -1,58 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| MODERNA | 44,300 | -0,74 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NOVAVAX | 7,300 | +1,11 % | Activist investor revives campaign to overhaul Novavax board | ||
| ILLUMINA | 108,68 | -0,93 % | ILLUMINA, INC. - 8-K, Current Report | ||
| NANOREPRO | 1,450 | 0,00 % | EQS-News: NanoRepro AG: Neues Vorstandsmitglied und Einleitung eines strategischen Reviewprozesses - Die Transformation nimmt Fahrt auf | EQS-News: NanoRepro AG
/ Schlagwort(e): Personalie/Sonstiges
NanoRepro AG: Neues Vorstandsmitglied und Einleitung eines strategischen Reviewprozesses - Die Transformation nimmt... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 0,956 | +1,86 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| INFLARX | 0,834 | +1,89 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,350 | +5,11 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 2,310 | -2,12 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,364 | -0,29 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| IBIO | 1,868 | +0,11 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen |
ERASCA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 16,940 Euro und damit -0,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERASCA INC finden Sie auf Wallstreet Online.